You just read:

Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors

News provided by

Daiichi Sankyo Company, Limited

Aug 28, 2017, 08:00 ET